Evommune, Inc. (EVMN)
NYSE:EVMN
Want to see EVMN full AI Analyst Report?
EVMN Stock Chart & Stats
$27.45
--
Market closed
$27.45
--
Day’s Range― - ―
52-Week Range$13.89 - $33.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)935.27K
Market Cap
$869.12M
Enterprise Value$253.29M
Total Cash (Recent Filing)$211.46M
Total Debt (Recent Filing)$9.11M
Price to Earnings (P/E)―
Beta0.58
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,018,370
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue25.33
Enterprise Value/Gross Profit27.31
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$51.80Price Target Upside88.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthMeaningful multi-year revenue growth demonstrates growing commercial traction and product adoption capacity. A rising top line strengthens gross profit potential and, if sustained, can reduce future financing needs and support gradual scaling of operations beyond the clinical phase.
Material Balance-sheet De-riskingA dramatic reduction in leverage and a positive equity position materially lower solvency risk and increase financial flexibility. This recapitalization provides optionality for funding R&D or partnerships and reduces bankruptcy risk, improving the company’s runway for executing its mid-term strategy.
Strong Cash Position And Pipeline ProgressA substantial cash reserve combined with advancing Phase 2b programs de-risks near-term funding and allows management to progress multiple indications. This funding cushion supports trial completion and regulatory milestones that can create durable value inflection points if clinical data are positive.
Bears Say
Worsening Operating Cash BurnOperating and free cash flows are deeply negative and accelerating, increasing reliance on external financing or dilution. Persistent rising cash burn is a structural risk for a clinical-stage biotech: it pressures liquidity planning and may force capital raises that alter shareholder economics if revenue does not scale.
Large Persistent Net LossesSubstantial recurring losses indicate the current cost base far exceeds revenue scale. Without sustained progress to profitability or transformational trial outcomes, the structural deficit threatens long-term sustainability and increases the probability of future financing that could dilute existing stakeholders.
Execution Risk Tied To Mid-stage Trial ReadoutsCommercial upside depends heavily on upcoming Phase 2b results and successful advancement into additional indications. Clinical failure, regulatory setbacks, or delays would materially curtail revenue prospects and likely force additional funding rounds, making execution risk a persistent structural concern.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $13.88 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $869.12M.
When is Evommune, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evommune, Inc.’s earnings last quarter?
Currently, no data Available
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 36,018,370 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.80 (88.71% Upside)
$51.80 (88.71% Upside)
Blogger Sentiment
Bullish
EVMN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-195.15%
Trailing 12-Months
Asset Growth
475.65%
Trailing 12-Months
Company Description
Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$51.80
▲(88.71% Upside)
Ownership Overview
52.56% Insiders
10.70% Mutual Funds
10.56% Other Institutional Investors
23.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---